Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis

Next Previous
Trial Profile

FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Therapeutic Use
  • Acronyms FLUTE
  • Sponsors Adare Pharmaceuticals

    • Most Recent Events

    • 27 Oct 2021 Results of post-hoc analysis examining the threshold for a clinically meaningful change in dysphagia frequency and the time to achieve this change, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
    • 27 Oct 2021 Results assessing dysphagia symptoms as measured by the patient reported outcomes for the symptoms of eosinophilic esophagitis (PROSE) diary by examining the safety, efficacy and pharmacokinetics of APT-1011 for eosinophilic esophagitis, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
    • 23 May 2021 Results (n=99)post-hoc analysis assessing the effect of APT-1011 treatment response rates overall and in patients with strictures and/or grade 2 rings presented at the Digestive Disease Week 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top